Archive: Publications
-
Underuse of exon mutational analysis for gastrointestinal stromal tumors
Increased use of EMA will improve clinical outcomes in both current and future patients by informing treatment plans and identifying new, potential therapeutic targets as the role of genetics in medicine continues to expand.
Category: News
-
Cholecystokinin Receptor-Targeted Polyplex Nanoparticle Inhibits Growth and Metastasis of Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) remains the most aggressive malignancy with the lowest 5-year survival rate of all cancers in part owing to the lack of tumor-specific therapy and the rapid metastatic nature of this cancer.
Category: News
-
Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers
TML-high rate varied widely among gastrointestinal cancers. Although MSI is conceivably the main driver for TML-high, other factors may be involved.
Category: News
-
Immuno‐Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD‐L1 Testing May Not Be Enough
PD-L1 testing alone fails to detect patients who may benefit from ICI. Lower PD-L1 thresholds and TML testing should be considered in future clinical trials.
Category: News
-
Deciding the Duration of Adjuvant Chemotherapy in a Patient With Stage III Colon Cancer: When Can Less Be More?
Patients with stage III colon cancer benefit from adjuvant chemotherapy with FOLFOX or CAPOX.
Category: News